Literature DB >> 2983091

Qualitative and quantitative analyses of Epstein-Barr virus early antigen diffuse component by western blotting enzyme-linked immunosorbent assay with a monoclonal antibody.

J C Lin, E I Choi, J S Pagano.   

Abstract

We report the use of monoclonal antibody against the early antigen diffuse component (anti-EA-D) of Epstein-Barr virus (EBV) to analyze, both qualitatively and quantitatively, the expression of EA-D in various human lymphoblastoid cell lines activated by chemical inducers. The kinetics of synthesis of EA-D in P3HR-1, B95-8, and Ramos/AW cells were similar in that they all reached the peak of synthesis on day 5 after induction. Surprisingly, no expression of EA-D was found in induced BJAB/GC, an EBV-genome-containing cell line. EBV-negative cell lines, BJAB and Ramos, were negative for EA-D. Raji cells had no detectable EA-D but responded rapidly to induction, reaching a peak on day 3. Superinfection of Raji cells also resulted in marked induction of EA-D, which reached a plateau between 8 to 12 h postinfection. Western blotting coupled with the enzyme-linked immunosorbent assay was employed to identify polypeptides representing EA-D. A family of four polypeptides with molecular weights of 46,000 (46K protein), 49,000, 52,000, and 55,000 were identified to be reactive with monoclonal anti-EA-D antiserum. The pattern of EA-D polypeptides expressed in each cell line was different. Of particular interest was the expression of a large quantity of 46K protein both in induced Raji and P3HR-1 cells, but not in superinfected Raji cells. A 49K doublet was expressed in activated p3HR-1, B95-8, and Ramos/AW cells and in superinfected Raji cells. In addition, two distinct 52K and 55K polypeptides were expressed in induced Ramos/AW and superinfected Raji cells. However, none of these EA-D polypeptides was detectable in BJAB/GC, BJAB, Ramos, and mock-infected Raji cells. To approximate relative concentrations of EA-D in cell extracts, we employed the enzyme-linked immunosorbent assay and immunoblot dot methods by using one of the purified EA-D components to construct a standard curve. Depending upon the cell lines, it was estimated that ca. 1 to 3% (determined by the enzyme-linked immunosorbent assay) and 0.8 to 1.6% (determined by immunoblot dot) of total proteins from maximally induced cells were EA-D. These results suggest that differential expression of EA-D polypeptides could be of importance in the diagnosis of state of EBV infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983091      PMCID: PMC254709     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

2.  Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells.

Authors:  G Henle; W Henle; G Klein
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

3.  Detection of Epstein-Barr viral genome in nonproductive cells.

Authors:  M Nonoyama; J S Pagano
Journal:  Nat New Biol       Date:  1971-09-22

4.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

5.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

6.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Authors:  E Engvall; P Perlmann
Journal:  Immunochemistry       Date:  1971-09

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Immunobiochemical characterization with monoclonal antibodies of Epstein-Barr virus-associated early antigens in chemically induced cells.

Authors:  A L Epstein
Journal:  J Virol       Date:  1984-05       Impact factor: 5.103

9.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

View more
  13 in total

1.  Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein.

Authors:  J Luka; G Miller; H Jörnvall; G R Pearson
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

2.  Two strains of Epstein-Barr virus (B95-8 and a P3HR-1 subclone) that lack defective genomes induce early antigen and cause abortive infection of Raji cells.

Authors:  J C Lin; N Raab-Traub
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

3.  Sequential detection of different antigens induced by Epstein-Barr virus and herpes simplex virus in the same Western blot by using dual antibody probes.

Authors:  J C Lin; J S Pagano
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Functional characterization of partially purified Epstein-Barr virus DNA polymerase expressed in the baculovirus system.

Authors:  J C Lin; B K De; E C Mar
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332

5.  Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity.

Authors:  J S Li; B S Zhou; G E Dutschman; S P Grill; R S Tan; Y C Cheng
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

6.  Atypical immune response to Epstein-Barr virus in major depressive disorder.

Authors:  Lorraine Jones-Brando; Faith Dickerson; Glen Ford; Cassie Stallings; Andrea Origoni; Emily Katsafanas; Kevin Sweeney; Amalia Squire; Sunil Khushalani; Robert Yolken
Journal:  J Affect Disord       Date:  2019-11-30       Impact factor: 4.839

7.  Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans.

Authors:  K M Wong; A J Levine
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

8.  Specific Epstein-Barr virus serological response in patients with nasopharyngeal carcinoma detected by immunoblotting.

Authors:  R Cevenini; M Donati; A Moroni; U Caliceti; A Rinaldi-Ceroni; M La Placa
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

9.  Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.

Authors:  Fu-Zhang Wang; Debasmita Roy; Edward Gershburg; Christopher B Whitehurst; Dirk P Dittmer; Joseph S Pagano
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

10.  A defined methodology for reliable quantification of Western blot data.

Authors:  Sean C Taylor; Thomas Berkelman; Geetha Yadav; Matt Hammond
Journal:  Mol Biotechnol       Date:  2013-11       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.